Zai Lab Limited (NASDAQ:ZLAB) said on Monday that China’s National Medical Products Administration has accepted the label ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and trospium chloride, for the treatment of schizophrenia in adults.

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Zai Lab (ZLAB – Research Report), with a price target of $55.00. The company’s shares closed last Friday at ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...